Shares of Revance Therapeutics took flight in early trading Monday after the biotechnology company agreed to be acquired by privately held skincare company Crown Laboratories.
Revance shares were recently changing hands at $6.53, up about 85%.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,